• Arjang Hassibi, Ph.D.
    Founder and Chief Executive Officer (CEO)
    Arjang Hassibi is the President, Chief Executive Officer, and a board member of InSilixa. He founded InSilixa in 2012 to commercialize the proprietary CMOS biosensor technologies that he had been developing in academia for almost a decade.Dr. Hassibi’s area of expertise is the intersection of biotechnology and engineering, specifically biosensors and bioelectronics, integrated array technologies, and DNA sequencing. Prior to starting InSilixa, he was a faculty member at the Electrical and Computer Engineering Department and the Institute for Cellular and Molecular Biology of The University of Texas at Austin. During his career, he has held various R&D positions in both industry and academia including Stanford Genome Technology Center, IBM Research at Yorktown, California Institute of Technology (Caltech), and Xagros Genomics, a startup company which he co-founded in 2001. Most recently, he was the Healthcare Thrust Lead at the Silicon Research Corporation (SRC), the world's leading semiconductor technology research consortium.Dr. Hassibi received his B.Sc. with the highest honors from the University of Tehran, Iran, and both his M.Sc. and Ph.D. degrees from Stanford University, all in electrical engineering. He attended Caltech for his postdoctoral training. Dr. Hassibi has more than 100 technical publications and patents, almost all in the multidisciplinary area of biosensors and bioelectronics.
  • Nader Gamini
    Chief Operating Officer (COO)
    Nader Gamini serves as Chief Operating Officer and a board member of InSilixa. He manages manufacturing, finance, corporate development, HR, and legal affairs of InSilixa. In addition, he is responsible for semiconductor packaging design and development, fluidics cartridge design, and instrument development.Nader has over 30 years of experience in high-volume, global manufacturing of electronics for commercial, military, and medical applications. He has served on the boards of directors of 4 companies, and has been an advisor to many companies in biotech, wireless communications, medical devices, solar, MEMS, optics, and other related industries. Prior to joining InSilixa in 2012, he was the VP of Manufacturing of the PLP Division of NetLogic Microsystem (acquired by Broadcom in 2012). From 2001 to 2007 he was the COO and co-founder of Aeluros (acquired by NetLogic Microsystems in 2007). Before Aeluros he was an executive of several companies with successful exits such as Rambus (IPO in 1997) and Sirenza Microdevices (IPO in 2000).Nader has a B.Sc. degree in computer science, and dropped out of UCLA’s MBA program to launch his first startup company. He has 9 issued patents in the area of high-performance semiconductor packaging and module technologies.
  • Bob Kuimelis, Ph.D.
    VP of Chemistry
    Bob Kuimelis serves as Vice President Chemistry for InSilixa and is responsible for array chemistries from manufacturing to assay, bridging disciplines and technology platform development. Bob previously held senior management positions at HealthTell, where he built up the technical operations and was responsible for process development of its central high-density peptide microarray platform for early disease detection. As Chemistry Director at Affymetrix for nearly 10 years, he led a department engaged in a range of multidisciplinary R&D programs, new technology development and process transfer & integration. Prior to Affy, he was one of the first to join Phylos (now Adnexus/BMS), a pioneering Boston area startup commercializing directed protein evolution and antibody mimetics. Bob launched his industrial career at Applied Biosystems following a productive postdoctoral stint at Boston College. His interests are at the interface of chemistry, biology and technology and the development of innovative platforms with broad potential to impact health. Bob received his B.Sc. in Chemistry from Saint Mary’s College of California, and his Ph.D. in Organic Chemistry from the University of California, Davis. He has coauthored 34 scientific publications and holds 29 issued U.S. Patents in the areas of engineered protein scaffolds, nucleic acid chemistry, surface chemistry and microarrays.